(Q51493311)

English

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

scientific article published in August 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16882108

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. (English)

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16882108

metabolic syndrome

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

circulatory system

1 reference

based on heuristic

inferred from title

Giuseppe Derosa

1

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16882108

Angela D'Angelo

2

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16882108

Arrigo F. Cicero

12

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16882108

author name string

Ragonesi PD

3

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16882108

Ciccarelli L

4

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16882108

Piccinni MN

5

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16882108

Pricolo F

6

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16882108

Salvadeo SA

7

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16882108

Montagna L

8

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16882108

Gravina A

9

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16882108

Ferrari I

10

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16882108

Paniga S

11

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16882108

publication date

1 August 2006

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16882108

Journal of Clinical Pharmacy and Therapeutics

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16882108

31

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16882108

4

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16882108

375-383

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16882108

Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00756.X

21 January 2018

Influence of lipoprotein(a) on restenosis after femoropopliteal percutaneous transluminal angioplasty in Type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00756.X

21 January 2018

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00756.X

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00756.X

21 January 2018

Determination of total serum insulin (IRI) in insulin-treated diabetic patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00756.X

21 January 2018

Atherothrombosis, inflammation, and diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00756.X

21 January 2018

Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00756.X

21 January 2018

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00756.X

21 January 2018

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00756.X

21 January 2018

Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00756.X

21 January 2018

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00756.X

21 January 2018

Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2006.00756.X

21 January 2018

Identifiers

10.1111/J.1365-2710.2006.00756.X

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16882108

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16882108

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51493311&oldid=1248211315"